Jay R. Venkatesan - 09 Feb 2021 Form 4/A - Amendment Insider Report for Angion Biomedica Corp. (ELTX)

Role
President and Chief Executive Officer and Director, Director
Signature
/s/ Jennifer J. Rhodes, as attorney-in fact for Jay. R. Venkatesan
Issuer symbol
ELTX
Transactions as of
09 Feb 2021
Net transactions value
+$4,595
Form type
4/A - Amendment
Filing time
27 May 2022, 16:20:09 UTC
Date Of Original Report
11 Feb 2021
Next filing
17 Dec 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELTX Common Stock Exercise of in-the-money or at-the-money derivative security $2,548,395 +396,329 +33% $6.43 1,598,440 09 Feb 2021 Direct
transaction ELTX Common Stock Sale $2,546,832 -159,177 -10% $16.00 1,367,263 09 Feb 2021 Direct F1
transaction ELTX Common Stock Conversion of derivative security $3,031 +262 +0.02% $11.57 1,439,525 09 Feb 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELTX Warrant to Purchase Common Stock Exercise of in-the-money or at-the-money derivative security $0 -396,329 -100% $0.000000* 0 09 Feb 2021 Common Stock 396,329 $6.43 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 9, 2021 the Reporting Person exercised a warrant to purchase an aggregate of 396,329 shares of the Issuer's common stock for $6.43 a share. The Reporting Person paid the exercise price on a cashless basis, resulting in the issuer's withholding of 159,177 of the warrant shares to pay the exercise price and issuing to the Reporting Person the remaining 237,152 shares of common stock.

Remarks:

President and Chief Executive Officer and Director